vitamin-b-12 and Tinnitus

This pilot study aimed to evaluate the feasibility effectiveness and safety of transcutaneous electrical nerve stimulation (TENS) for patients with acute tinnitus.. A total of 46 eligible patients with acute tinnitus were entered and included in this randomized controlled trial. All the included patients were equally and randomly divided into a verum TENS group and a sham TENS group, each group 23 participants. All patients received parenteral intramuscular therapy of 1 ml Vitamin B12 weekly for a total of 4 weeks. In addition, they also underwent verum or sham TENS 30 min daily, 3 times weekly for 4 weeks. The primary efficacy endpoint was measured by the Tinnitus Severity Scale (TSS) and Tinnitus Questionnaire (TQ) sum score. The secondary efficacy endpoints were assessed by the Tinnitus Handicap Inventory (THI), 12-Item Short Form Health Survey (SF-12) questionnaire, and adverse events. All outcome efficacy endpoints were measured at baseline and after 4 weeks of treatment.. After 4-week treatment, the patients undergoing verum TENS showed statistically efficacy of symptoms relief, as measured by the scales of TSS (P < .01), TQ (P < .01), and THI (P < .01), and improvement of quality of life, as assessed by the SF-12 (P < .01), compared with patients receiving sham TENS. In addition, no adverse events related to the treatment were recorded in either group.. The results of this study showed that verum TENS may benefit patients with acute tinnitus after 4 weeks of treatment.

Topics: Acute Disease; Adult; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Parenteral Nutrition; Pilot Projects; Quality of Life; Severity of Illness Index; Surveys and Questionnaires; Tinnitus; Transcutaneous Electric Nerve Stimulation; Treatment Outcome; Vitamin B 12

Abtract Objective: The auditory brainstem response (ABR) has been reported as normal in patients with vitamin B12 deficiency, but there have also been reported cases of interference in amplitude responses. However, studies investigating the effects of vitamin B12 on auditory response are limited in patients with tinnitus. The aim of this study was to investigate the ABR findings in patients with tinnitus together with vitamin B12 deficiency.. Twenty-eight patients with tinnitus-related vitamin B12 deficiency were included in the study. Their serum vitamin B12 levels were lower than 200 pg/ml. Patients were between 19 and 58 years with a mean age of 36.82 ± 11.19 (ratio: male/female, 6/22). ABR was performed in all patients. Latencies ( I, II, III, IV, V), interpeak latencies (I-III, III-V, I-V) and amplitudes were evaluated. Neurologic and ear physical examinations were evaluated and brain magnetic resonance imaging (MRI) was also performed in all patients.. Neurologic,ear-auditory physical examinations and brain MRI findings were normal in all patients. Wave latencies and interpeak latencies were normal in all patients. Six patients (21.42 %) had low amplitude in their ABR. In one of them, the left-sided response showed a mild amplitude decrease in all waves compared to the right-side. Bilateral mild low amplitude was observed in 4 (66.6 %) patients in ABR findings.. These results support that ABR findings can be influenced in vitamin B12 deficiency patients having tinnitus. More detailed studies are needed in tinnitus associated with vitamin B12 deficient patients. Key words: Auditory brainstem response, Tinnitus, Vitamin B12 deficiency, Neurophysiology, Low amplitude.

Topics: Adult; Evoked Potentials, Auditory, Brain Stem; Female; Humans; Male; Middle Aged; Tinnitus; Vitamin B 12; Vitamin B 12 Deficiency

To assess possible delayed recovery of the maximum speech discrimination score (SDS) when the audiometric threshold ceases to change.. We retrospectively examined 20 patients with idiopathic sudden sensorineural hearing loss (ISSNHL) (gender: 9 males and 11 females, age: 24-71 years). The findings of pure-tone average (PTA), maximum SDS, auditory brainstem responses (ABRs), and tinnitus handicap inventory (THI) were compared among the three periods of 1-3 months, 6-8 months, and 11-13 months after ISSNHL onset.. No significant differences were noted in PTA, whereas an increase of greater than or equal to 10% in maximum SDS was recognized in 9 patients (45%) from the period of 1-3 months to the period of 11-13 months. Four of the 9 patients showed 20% or more recovery of maximum SDS. No significant differences were observed in the interpeak latency difference between waves I and V and the interaural latency difference of wave V in ABRs, whereas an improvement in the THI grade was recognized in 11 patients (55%) from the period of 1-3 months to the period of 11-13 months.. The present study suggested the incidence of maximum SDS restoration over 1 year after ISSNHL onset. These findings may be because of the effects of auditory plasticity via the central auditory pathway.

Topics: Adenosine Triphosphate; Adrenal Cortex Hormones; Adult; Aged; Audiometry, Pure-Tone; Dexamethasone; Evoked Potentials, Auditory, Brain Stem; Female; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Injection, Intratympanic; Male; Middle Aged; Recovery of Function; Retrospective Studies; Speech Discrimination Tests; Speech Perception; Surveys and Questionnaires; Time Factors; Tinnitus; Vitamin B 12; Vitamin B Complex; Young Adult

We surveyed the benefit of dietary supplements to treat tinnitus and reported adverse effects.. A website was created for people with tinnitus to complete a variety of questions.. The 1,788 subjects who responded to questionnaires came from 53 different countries; 413 (23.1%) reported taking supplements. No effect on tinnitus was reported in 70.7%, improvement in 19.0%, and worsening in 10.3%. Adverse effects were reported in 6% (n = 36), including bleeding, diarrhea, headache, and others. Supplements were reported to be helpful for sleep: melatonin (effect size, d = 1.228) and lipoflavonoid (d = 0.5244); emotional reactions: melatonin (d = 0.6138) and lipoflavonoid (d = 0.457); hearing: Ginkgo biloba (d = 0.3758); and concentration Ginkgo biloba (d = 0.3611). The positive, subjective reports should be interpreted cautiously; many might have reported a positive effect because they were committed to treatment and expected a benefit. Users of supplements were more likely to have loudness hyperacusis and to have a louder tinnitus.. The use of dietary supplements to treat tinnitus is common, particularly with Ginkgo biloba, lipoflavonoids, magnesium, melatonin, vitamin B12, and zinc. It is likely that some supplements will help with sleep for some patients. However, they are generally not effective, and many produced adverse effects. We concluded that dietary supplements should not be recommended to treat tinnitus but could have a positive outcome on tinnitus reactions in some people.

Topics: Central Nervous System Depressants; Cross-Sectional Studies; Dietary Supplements; Female; Flavonoids; Ginkgo biloba; Humans; Hyperacusis; Magnesium; Male; Melatonin; Middle Aged; Plant Extracts; Surveys and Questionnaires; Tinnitus; Trace Elements; Vitamin B 12; Vitamin B Complex; Zinc

Some patients with sudden sensorineural hearing loss (SSNHL) are frustrated by residual tinnitus even after accomplishment of the treatment for SSNHL. In the present prospective study, we examined patients' backgrounds of sex, laterality and age together with changes in hearing level and the tinnitus score after the onset of SSHNL to determine the prognostic factors of residual tinnitus after the final day of medical treatment for SSNHL.. Forty-four patients with SSNHL were all treated with systemic administration of steroids for 2 weeks and oral intake of vasoactive drugs and vitamin B12 for 6 months before accomplishment of the treatment for SSNHL. The hearing improvement rate (HIR) was determined by comparing the hearing level before and 6 months after the start of treatment. Tinnitus was subjectively evaluated by the tinnitus scoring questionnaire before, 6 and 24 months after the start of treatment. The score of a five-step evaluation of subjective tinnitus feelings, "loudness", "duration" and "annoyance", was recorded.. HIR was significantly correlated with tinnitus score improvement (TSI) in "duration" at 6 months after the start of treatment compared with before treatment. The tinnitus score of all 3 items was significantly improved 6 months after the start of treatment compared with that before treatment but it was not significantly changed between 6 and 24 months after the start of treatment. TSI in "duration" between 6 and 24 months was significantly correlated with the patients' age and HIR using multiple regression analysis.. According to the tinnitus scoring questionnaire, "duration" is the most reliable item for subjective evaluation of tinnitus accompanied by SSNHL. Generally, subjective feelings for residual tinnitus 6 months after the start of treatment for SSNHL are supposed to be almost the same, even at the 24th post-treatment month. Especially, younger patients with better hearing improvement are predicted to achieve further improvement of tinnitus between 6 and 24 months after the start of treatment.

Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Audiometry, Pure-Tone; Cardiovascular Agents; Female; Hearing Loss, Sudden; Humans; Hydrocortisone; Male; Middle Aged; Prognosis; Prospective Studies; Recovery of Function; Sex Factors; Surveys and Questionnaires; Tinnitus; Treatment Outcome; Vitamin B 12; Vitamin B Complex; Young Adult

To determine the correlation between plasma levels of melatonin, vitamin C and vitamin B12 and the presence of tinnitus among elderly subjects with unexplained subjective tinnitus.. Prospective involving apparently healthy elderly with subjective tinnitus and those without. Plasma levels of melatonin, vitamin C and vitamin B12 were determined using high performance liquid chromatography and correlation determined by comparing subjects with and without tinnitus.. There were 139 elderly subjects (78 females and 61males), the mean(SD) range of the age was 66.9years (0.77) 60-98 years. Of these 58.3% had tinnitus. The mean (SD) range of the plasma levels of melatoninn was 11.2 pg/mL(4.2) 5.1 pg/mL - 30.2 pg/mL while that of Vitamin C was 0.7 µmol/L (0.1) 0.3 µmol/L - 1.2 µmol/L, and vitamin B12 was 43.0pmol/L (3.1) 25.4 pmol/L - 71.6pmol/L. Comparing the plasma levels of the markers between elderly with and those without tinnitus, the plasma levels of melatonin (p=0.01) and vitamin B12 (p=0.03) were significantly lower among the elderly with tinnitus compared to those without, while the difference in the plasma level of vitamin C (p=0.6) was not.. Low plasma melatonin and vitamin B12 have significant correlation with the development of subjective idiopathic tinnitus among the elderly. This finding suggests the need for the trial of correction of these markers in the reversal or control of tinnitus.

Topics: Aged; Aged, 80 and over; Ascorbic Acid; Chromatography, High Pressure Liquid; Female; Humans; Male; Melatonin; Middle Aged; Prospective Studies; Tinnitus; Vitamin B 12

Ninety-eight patients with idiopathic sudden deafness were treated with a modified defibrinogenation (DF) therapy including batroxobin, low molecular dextran, vasodilators and vitamins. Hearing improvement was evaluated with two methods: categorical judgement and improvement rate (%). By categorical judgement, 60 patients (61% of the total) were classified into recovery or good improvement categories. The improvement rate was calculated for each of the 93 patients, and the average value was 64%. Modified DF therapy was effective especially for patients with severe hearing loss of 70-90 dB with flat audiogram. Although serum fibrinogen significantly decreased after batroxobin administration there was no correlation between the concentration of fibrinogen and hearing recovery. When prognostic factors were studied, the interval between the onset of hearing loss and start of treatment, initial hearing level, and the existence of vertigo all had significant correlation with the degree of hearing recovery.

Topics: Adenosine Triphosphate; Adolescent; Adult; Aged; Aged, 80 and over; Audiometry, Pure-Tone; Batroxobin; Dextrans; Female; Fibrinogen; Flunarizine; Hearing; Hearing Loss, Sudden; Humans; Male; Middle Aged; Prognosis; Time Factors; Tinnitus; Vertigo; Vitamin B 12

Topics: Adult; Aged; Brachial Plexus Neuritis; Child; Child, Preschool; Headache; Humans; Hypnotics and Sedatives; Middle Aged; Migraine Disorders; Plant Extracts; Plants, Medicinal; Pyridoxine; Thiamine; Tinnitus; Tranquilizing Agents; Valerian; Vitamin B 12

Topics: Biomedical Research; Deafness; Drug Therapy; Hearing Disorders; Hearing Loss; Humans; Paralysis; Recurrent Laryngeal Nerve; Tinnitus; Vitamin B 12; Vocal Cord Paralysis